One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Apogee Therapeutics now clears that threshold, with a jump from 77 to 81 Wednesday.
IBD's unique rating measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an 80 or better RS Rating as they launch their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
While now is not an ideal time to buy shares, see if the stock manages to offer and clear an appropriate buy point.
Apogee Therapeutics reported 0% EPS growth in the latest quarterly report. Revenue gains came in at 0%.
Apogee Therapeutics holds the No. 234 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!